A detailed history of China Universal Asset Management Co., Ltd. transactions in Erasca, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 54,335 shares of ERAS stock, worth $152,681. This represents 0.02% of its overall portfolio holdings.

Number of Shares
54,335
Previous 30,527 77.99%
Holding current value
$152,681
Previous $72,000 105.56%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$2.17 - $3.28 $51,663 - $78,090
23,808 Added 77.99%
54,335 $148,000
Q2 2024

Jul 19, 2024

BUY
$1.79 - $2.63 $2,710 - $3,981
1,514 Added 5.22%
30,527 $72,000
Q1 2024

Apr 29, 2024

BUY
$1.67 - $2.55 $19,273 - $29,429
11,541 Added 66.05%
29,013 $60,000
Q4 2023

May 21, 2024

SELL
$1.67 - $2.49 $19,273 - $28,737
-11,541 Reduced 39.78%
17,472 $37,000
Q4 2023

Jan 23, 2024

BUY
$1.67 - $2.49 $22,706 - $33,856
13,597 Added 350.89%
17,472 $37,000
Q3 2023

May 21, 2024

BUY
$1.97 - $2.91 $3,741 - $5,526
1,899 Added 96.1%
3,875 $7,000
Q3 2023

Oct 30, 2023

BUY
$1.97 - $2.91 $3,741 - $5,526
1,899 Added 96.1%
3,875 $8,000
Q2 2023

May 21, 2024

BUY
$2.57 - $3.3 $280 - $359
109 Added 5.84%
1,976 $5,000
Q2 2023

Jul 27, 2023

BUY
$2.57 - $3.3 $280 - $359
109 Added 5.84%
1,976 $5,000
Q1 2023

May 21, 2024

BUY
$2.74 - $4.44 $1,709 - $2,770
624 Added 50.2%
1,867 $5,000
Q1 2023

Apr 27, 2023

BUY
$2.74 - $4.44 $1,709 - $2,770
624 Added 50.2%
1,867 $6,000
Q4 2022

May 21, 2024

SELL
$3.89 - $8.57 $108,025 - $237,988
-27,770 Reduced 95.72%
1,243 $5,000
Q4 2022

Jan 31, 2023

BUY
$3.89 - $8.57 $385 - $848
99 Added 8.65%
1,243 $5,000
Q3 2022

Oct 21, 2022

BUY
$5.82 - $10.68 $6,658 - $12,217
1,144 New
1,144 $9,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $343M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.